An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer

International Journal of Cancer

Volumn 132, Issue 2, 2013, Pages 485-494

  Tsuji, Toshiaki ^a   Nakamori, Mikihito ^a   Iwahashi, Makoto ^a   Nakamura, Masaki ^a   Ojima, Toshiyasu ^a   Iida, Takeshi ^a   Katsuda, Masahiro ^a   Hayata, Keiji ^a   Ino, Yasushi ^b   Todo, Tomoki ^b   Yamaue, Hiroki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

antiangiogenesis; gastric cancer; herpes simplex virus; oncolytic virus; thrombospondin 1

Indexed keywords

ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS; T 01; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; GENE CONSTRUCT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; STOMACH CANCER; TUMOR XENOGRAFT; VIRUS INHIBITION;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CLONING, MOLECULAR; FEMALE; GENE EXPRESSION; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SIMPLEXVIRUS; STOMACH NEOPLASMS; THROMBOSPONDIN 1; TUMOR BURDEN; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869492617     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27681     Document Type: Article

References (43)

1. Crew KD, Neugut AI,. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354-62.
2. Hohenberger P, Gretschel S,. Gastric cancer. Lancet 2003; 362: 305-15.
3. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000; 7: 859-66.
4. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867-74.
5. Kemeny N, Brown K, Covey A, et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 2006; 17: 1214-24.
6. Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12: 6737-47.
7. Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010; 17: 718-30.
8. Nakamori M, Fu X, Meng F, et al. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin Cancer Res 2003; 9: 2727-33.
9. Nakamori M, Fu X, Rousseau R, et al. Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol Ther 2004; 9: 658-65.
10. Nakamori M, Fu X, Pettaway CA, et al. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate 2004; 60: 53-60.
11. Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 2001; 98: 6396-401.
12. Aghi M, Rabkin SD, Martuza RL,. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res 2007; 67: 440-4.
13. Kurozumi K, Hardcastle J, Thakur R, et al. Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 2008; 16: 1382-91.
14. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, et al. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994; 54: 6504-11.
15. Sheibani N, Frazier WA,. Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc Natl Acad Sci USA 1995; 92: 6788-92.
16. Volpert OV, Dameron KM, Bouck N,. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 1997; 14: 1495-502.
17. Dawson DW, Pearce SF, Zhong R, et al. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997; 138: 707-17.
18. Manna PP, Frazier WA,. CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A. Cancer Res 2004; 64: 1026-36.
19. Saumet A, Slimane MB, Lanotte M, et al. Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells. Blood 2005; 106: 658-67.
20. Yee KO, Streit M, Hawighorst T, et al. Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-β. Am J Pathol 2004; 165: 541-52.
21. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001; 98: 12485-90.
22. Hardcastle J, Kurozumi K, Dmitrieva N, et al. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 2009; 18: 285-94.
23. Campbell NE, Greenaway J, Henkin J, et al. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia 2010; 12: 275-83.
24. Fukuhara H, Ino Y, Kuroda T, et al. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res 2005; 65: 10663-8.
25. Liu TC, Zhang T, Fukuhara H, et al. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res 2006; 12: 6791-9.
26. Fu X, Tao L, Jin A, et al. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 2003; 7: 748-54.
27. Fu X, Tao L, Rivera A, et al. Virotherapy induces massive infiltration of neutrophils in a subset of tumors defined by a strong endogenous interferon response activity. Cancer Gene Ther 2011; 18: 785-94.
28. Fu X, Nakamori M, Tao L, et al. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. Int J Oncol 2007; 30: 1561-7.
29. Tenan M, Fulci G, Albertoni M, et al. Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells. J Exp Med 2000; 191: 1789-98.
30. Jo WS, Mizukami Y, Duerr EM, et al. Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis. Cancer Biol Ther 2005; 4: 1361-6.
31. Choudhary A, Hiscott P, Hart CA, et al. Suppression of thrombospondin 1 and 2 production by herpes simplex virus 1 infection in cultured keratocytes. Mol Vis 2005; 11: 163-8.
32. Streit M, Velasco P, Brown LF, et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999; 155: 441-52.
33. Greenaway J, Henkin J, Lawler J, et al. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther 2009; 8: 64-74.
34. Miao WM, Seng WL, Duquette M, et al. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res 2001; 61: 7830-9.
35. Wong J, Kelly K, Mittra A, et al. A third-generation herpesvirus is effective against gastroesophageal cancer. J Surg Res 2010; 163: 214-20.
36. Wood LW, Shillitoe EJ,. Effect of a caspase inhibitor, zVADfmk, on the inhibition of breast cancer cells by herpes simplex virus type 1. Cancer Gene Ther 2011; 18: 685-94.
37. Leopardi R, Roizman B,. The herpes simplex virus major regulatory protein ICP4 blocks apoptosis induced by the virus or by hyperthermia. Proc Natl Acad Sci USA 1996; 93: 9583-7.
38. Benetti L, Roizman B,. Herpes simplex virus protein kinase US3 activates and functionally overlaps protein kinase A to block apoptosis. Proc Natl Acad Sci USA 2004; 101: 9411-16.
39. Ahmed M, Lock M, Miller CG, et al. Regions of the herpes simplex virus type 1 latency-associated transcript that protect cells from apoptosis in vitro and protect neuronal cells in vivo. J Virol 2002; 76: 717-29.
40. Komuro A, Yashiro M, Iwata C, et al. Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling. J Natl Cancer Inst 2009; 101: 592-604.
41. Guo N, Templeton NS, Al-Barazi H, et al. Thrombospondin-1 promotes alpha3beta1 integrin-mediated adhesion and neurite-like outgrowth and inhibits proliferation of small cell lung carcinoma cells. Cancer Res 2000; 60: 457-66.
42. Lih CJ, Wei W, Cohen SN,. Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev 2006; 20: 2082-95.
43. Lin SF, Gao SP, Price DL, et al. Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin Cancer Res 2008; 14: 1519-28.